High prevalence of occult hepatitis C virus infection in patients with primary and secondary glomerular nephropathies

Kidney International

Volumn 86, Issue 3, 2014, Pages 619-624

  Castillo, Inmaculada ^a   Martinez Ara, Jorge ^b   Olea, Teresa ^b   Bartolomé, Javier ^a   Madero, Rosario ^b   Hernández, Eduardo ^c,d   Bernis, Carmen ^e   Aguilar, Ana ^b   Quiroga, Juan A ^a   Carrẽo, Vicente ^a   Selgas, Rafael ^b,d  

^a Fundacion para el Estudio de Las Hepatitis Virales   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d REDINREN   (Spain)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

glomerulonephritis; hepatitis; occult HCV; PBMCs

Indexed keywords

CREATININE; VIRUS RNA; HEPATITIS C ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HEPATITIS C; HUMAN; IMMUNE COMPLEX NEPHRITIS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; RNA ANALYSIS; AGED; BLOOD; GENETICS; GLOMERULONEPHRITIS; HEPACIVIRUS; IMMUNOLOGY; MIDDLE AGED; MONONUCLEAR CELL; NEPHRITIS, HEREDITARY; PREVALENCE; PROSPECTIVE STUDY; VIROLOGY;

ADULT; AGED; CREATININE; FEMALE; GLOMERULONEPHRITIS; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEPHRITIS, HEREDITARY; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL;

EID: 84907597204     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.68     Document Type: Article

References (38)

1. Jacobson IM, Cacoub P, Dal Maso L et al. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol 2010; 8: 1017-1029.
2. Blackard JT, Kemmer N, Sherman KE. Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology 2006; 44: 5-22.
3. Rodriguez-Iñigo E, Casqueiro M, Bartolomé J et al. Hepatitis C virus RNA in kidney biopsies from infected patients with renal diseases. J Viral Hepat 2000; 7: 23-29.
4. Johnson RJ, Gretch DR, Yamabe H et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328: 465-470.
5. Latt N, Alachkar N, Gurakar A. Hepatitis C virus and its renal manifestations: a review and update. Gastroenterol Hepatol (NY) 2012; 8: 434-445.
6. Kamar N, Izopet J, Alric L et al. Hepatitis C virus-related kidney disease: an overview. Clin Nephrol 2008; 69: 149-160.
7. Sansonno D, Dammacco F. Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Infect Dis 2005; 5: 227-236.
8. Barsoum RS. Hepatitis C virus: from entry to renal injury-facts and potentials. Nephrol Dial Transplant 2007; 22: 1840-1848.
9. Sansonno D, Lauletta G, Nisi L et al. Non-enveloped HCV core protein as constitutive antigen of cold-precipitable immune complexes in type II mixed cryoglobulinaemia. Clin Exp Immunol 2003; 133: 275-282.
10. Ghany MG, Strader DB, Thomas DL et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
11. Chamie G, Bonacini M, Bangsberg DR et al. Factors associated with seronegative chronic hepatitis C virus infection in HIV infection. Clin Infect Dis 2007; 44: 577-583.
12. Hadlich E, Alvares-Da-Silva MR, Dal Molin RK et al. Hepatitis C virus (HCV) viremia in HIV-infected patients without HCV antibodies detectable by third-generation enzyme immunoassay. J Gastroenterol Hepatol 2007; 22: 1506-1509.
13. Schneeberger PM, Keur I, van Loon AM et al. The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study. J Infect Dis 2000; 182: 1291-1299.
14. Hanuka N, Sikuler E, Tovbin D et al. Hepatitis C virus infection in renal failure patients in the absence of anti-hepatitis C virus antibodies. J Viral Hepat 2002; 9: 141-145.
15. Schmidt WN, Wu P, Cederna J et al. Surreptitious hepatitis C virus (HCV) infection detected in the majority of patients with cryptogenic chronic hepatitis and negative HCV antibody tests. J Infect Dis 1997; 176 : 27-33.
16. Zanetti AR, Tanzi E, Zehender G et al. Hepatitis C virus RNA in symptomless donors implicated in post-transfusion non-A, non-B hepatitis. Lancet 1990; 336: 448.
17. Villa E, Ferretti I, De Palma M et al. HCV RNA in serum of asymptomatic blood donors involved in post-transfusion hepatitis (PTH). J Hepatol 1991; 13: 256-259.
18. Brojer E, Gronowska A, Medyńska J et al. The hepatitis C virus genotype and subtype frequency in hepatitis C virus RNA-positive, hepatitis C virus antibody-negative blood donors identified in the nucleic acid test screening program in Poland. Transfusion 2004; 44: 1706-1710.
19. Challine D, Pellegrin B, Bouvier-Alias M et al. HIV and hepatitis C virus RNA in seronegative organ and tissue donors. Lancet 2004; 364: 1611-1612.
20. Tugwell BD, Patel PR, Williams IT et al. Transmission of hepatitis C virus to several organ and tissue recipients from an antibody-negative donor. Ann Intern Med 2005; 143: 648-654.
21. Castillo I, Pardo M, Bartolomé J et al. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 2004; 189: 7-14.
22. Bartolomé J, López-Alcorocho JM, Castillo I et al. Ultracentrifugation of serum samples allows detection of hepatitis C virus RNA in patients with occult hepatitis C. J Virol 2007; 81: 7710-7715.
23. Bokharaei-Salim F, Keyvani H, Monavari SH et al. Occult hepatitis C virus infection in Iranian patients with cryptogenic liver disease. J Med Virol 2011; 83: 989-995.
24. Keyvani H, Bokharaei-Salim F, Monavari SH et al. Occult hepatitis C virus infection in candidates for liver transplant with cryptogenic cirrhosis. Hepat Mon 2013; 13: e11290.
25. Hernandez BY, Zhu X, Kwee S et al. Viral hepatitis markers in liver tissue in relation to serostatus in hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2013; 22: 2016-2023.
26. Farahani M, Bokharaei-Salim F, Ghane M et al. Prevalence of occult hepatitis C virus infection in Iranian patients with lymphoproliferative disorders. J Med Virol 2013; 85: 235-240.
27. Barril G, Castillo I, Arenas MD et al. Occult hepatitis C virus infection among hemodialysis patients. J Am Soc Nephrol 2008; 19: 2288-2292.
28. De Marco L, Gillio-Tos A, Fiano V et al. Occult HCV infection: an unexpected finding in a population unselected for hepatic disease. PLoS One 2009; 4: e8128.
29. De Marco L, Manzini P, Trevisan M et al. Prevalence and follow-up of occult HCV infection in an Italian population free of clinically detectable infectious liver disease. PLoS One 2012; 7: e43541.
30. Allam R, Lichtnekert J, Moll AG et al. Viral RNA and DNA trigger common antiviral responses in mesangial cells. J Am Soc Nephrol 2009; 20: 1986-1996.
31. Wörnle M, Schmid H, Banas B et al. Novel role of Toll-like receptor 3 in hepatitis C-associated glomerulonephritis. Am J Pathol 2006; 168: 370-385.
32. Bataille S, Kaplanski G, Boucraut J et al. Membranoproliferative glomerulonephritis and mixed cryoglobulinemia after hepatitis C virus infection secondary to glomerular NS3 viral antigen deposits. Am J Nephrol 2012; 35: 134-140.
33. Kong D, Wu D, Wang T et al. Detection of viral antigens in renal tissue of glomerulonephritis patients without serological evidence of hepatitis B virus and hepatitis C virus infection. Int J Infect Dis 2013; 17: e535-e538.
34. Perico N, Cattaneo D, Bikbov B et al. Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol 2009; 4: 207-220.
35. Casato M, Lagana B, Pucillo LP et al. Interferon for hepatitis C virusnegative type II mixed cryoglobulinemia. N Engl J Med 1998; 338: 1386-1387.
36. Casato M, Lilli D, Donato G et al. Occult hepatitis C virus infection in type II mixed cryoglobulinaemia. J Viral Hepat 2003; 10: 455-459.
37. Kwok S, Higuchi R. Avoiding false positive with PCR. Nature 1989; 339: 237-238.
38. Tamura K, Dudley J, Nei M et al. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Bio Evol 2007; 24: 1596-1599.